• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen is pleased to invite you to an upcoming webinar on March 30, 2026, at 15:00 GMT | 16:00 CET

Mar 30, 2026 | 2026, Events, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link or contact us at IR@philogen.com for further details.

Il Consiglio di Amministrazione approva il progetto di bilancio di esercizio e il bilancio consolidato al 31 dicembre 2025 (Price sensitive)

Mar 27, 2026 | 2026, Investors, Press Releases

more details

The Board of Directors approves the draft financial statements and the consolidated financial statements as of december 31st, 2025 (courtesy translation) (Price sensitive)

Mar 27, 2026 | 2026, Investors, Press Releases

more details

Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.

Nov 20, 2025 | 2025, Events, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link in the description or contact usat IR@philogen.com for further details.

The Board of Directors approves the financial position for the third quarter of 2025

Nov 11, 2025 | 2025, Investors, Press Releases

more details

Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al terzo trimestre 2025

Nov 11, 2025 | 2025, Investors, Press Releases

more details
« Older Entries
Next Entries »

Recent Posts

  • Deposito del Verbale dell’Assemblea degli Azionisti
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026
  • The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)
  • Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026
  • Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it